Angelalign Technology Inc. disclosed a positive profit alert for the six months ended 30 June 2026, projecting double-digit growth across key operating and financial indicators.

Clear aligner volume grew 40.20% year on year to about 316,600 cases. Shipments outside mainland China rose 43.30% to approximately 168,000 cases, while mainland demand increased 36.80% to roughly 148,600 cases.

Revenue is expected to reach USD229.00 million – USD231.00 million, a rise of 41.90% – 43.10% from USD161.40 million in 2025 H1. Net profit is estimated at USD24.00 million – USD25.40 million, up 69.00% – 78.90% from USD14.20 million a year earlier.

Management attributes the performance to stronger clinician preference for clinically proven aligners, operating leverage from past investments in direct sales and local service infrastructure, and accelerated product and service innovation driven by a globally integrated professional team.

The interim results are unaudited and subject to finalisation; the full 2026 H1 report is slated for release before the end of August 2026. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.